Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew F Brown

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Current Topics in Medicinal Chemistry|June 12, 2010
CCR1 antagonists: what have we learned from clinical trialsRonald P Gladue, Matthew F Brown, Samuel H Zwillich
Current Opinion in Investigational Drugs (London, England : 2000)|June 19, 2004
CCR1 antagonists for the treatment of autoimmune diseasesRonald P Gladue, Samuel H Zwillich, Alan T Clucas, et al.
Nature Reviews. Drug Discovery|February 22, 2023
Delivering on the promise of protein degradersMatthew N O'Brien Laramy, Suman Luthra, Matthew F Brown, et al.
Chronic Stress (Thousand Oaks, Calif.)|May 23, 2020
Assessing Post-Traumatic Tonic Immobility Responses: The Scale for Tonic Immobility Occurring Post-TraumaChantelle S Lloyd, Ruth A Lanius, Matthew F Brown, et al.
Plos One|August 23, 2012
The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMAJing Sun, Quanhong Sun, Matthew F Brown, et al.
Nature Communications|March 2, 2023
A covalent BTK ternary complex compatible with targeted protein degradationJames Schiemer, Andrew Maxwell, Reto Horst, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 28, 2016
Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance MechanismsLouis Leung, Xin Yang, Timothy J Strelevitz, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2013
Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosaAndrew P Tomaras, Jared L Crandon, Craig J McPherson, et al.
Cancer Research|December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsSebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
Oncotarget|December 15, 2016
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylateJessica L Rausch, Sergei Boichuk, Areej A Ali, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Current Topics in Medicinal Chemistry|June 12, 2010
CCR1 antagonists: what have we learned from clinical trialsRonald P Gladue, Matthew F Brown, Samuel H Zwillich
Current Opinion in Investigational Drugs (London, England : 2000)|June 19, 2004
CCR1 antagonists for the treatment of autoimmune diseasesRonald P Gladue, Samuel H Zwillich, Alan T Clucas, et al.
Nature Reviews. Drug Discovery|February 22, 2023
Delivering on the promise of protein degradersMatthew N O'Brien Laramy, Suman Luthra, Matthew F Brown, et al.
Chronic Stress (Thousand Oaks, Calif.)|May 23, 2020
Assessing Post-Traumatic Tonic Immobility Responses: The Scale for Tonic Immobility Occurring Post-TraumaChantelle S Lloyd, Ruth A Lanius, Matthew F Brown, et al.
Plos One|August 23, 2012
The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMAJing Sun, Quanhong Sun, Matthew F Brown, et al.
Nature Communications|March 2, 2023
A covalent BTK ternary complex compatible with targeted protein degradationJames Schiemer, Andrew Maxwell, Reto Horst, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 28, 2016
Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance MechanismsLouis Leung, Xin Yang, Timothy J Strelevitz, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2013
Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosaAndrew P Tomaras, Jared L Crandon, Craig J McPherson, et al.
Cancer Research|December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsSebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
Oncotarget|December 15, 2016
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylateJessica L Rausch, Sergei Boichuk, Areej A Ali, et al.
Pageof 4